Browsing Category

64026 posts
Swan Lake's Grand Return in Malaysia After Years

Swan Lake's Grand Return in Malaysia After Years

Crescendo, a division of the renowned Primuse Group, announces the commencement of…
Emeren Group Announces Preliminary 2023 Financials and 2024 Outlook

Emeren Group Announces Preliminary 2023 Financials and 2024 Outlook

STAMFORD, Conn., Jan. 25, 2024 /PRNewswire/ — Emeren Group Ltd ("Emeren" or…
Growth Reimagined: G-P Announces Record Customer Growth and Momentum in 2023

Growth Reimagined: G-P Announces Record Customer Growth and Momentum in 2023

Recognized leader in employer of record (EOR) industry touts banner business growth…
Rogers International Commodity Index (RICI®) Composition Unchanged

Rogers International Commodity Index (RICI®) Composition Unchanged

SINGAPORE, Jan. 25, 2024 /PRNewswire/ — Following the annual meeting of the…
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in…
Reebelo encourages Aussies to make the switch to sustainable tech this New Year

Reebelo encourages Aussies to make the switch to sustainable tech this New Year

Reebelo has been giving Australian consumers access to affordable, trustworthy and sustainable…
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in…